Domain: Clinical Research & Immunology (Vaccinology)
Persona: Senior Medical Research Lead / Clinical Trial Analyst
Tone/Vocabulary: High-level clinical terminology (e.g., relative vaccine efficacy, reactogenicity, noninferiority margins, HAI assays). The focus is on statistical significance, safety signals, and comparative immunogenicity.
Abstract
This Phase 3 randomized, blinded clinical trial (NCT05540522) evaluates the efficacy, immunogenicity, and safety of a quadrivalent nucleoside-modified messenger RNA (modRNA) influenza vaccine compared to a licensed inactivated quadrivalent vaccine. Conducted during the 2022–2023 season with 18,476 participants (ages 18–64), the study assessed relative vaccine efficacy (RVE) against laboratory-confirmed influenza-like illness (ILI). The modRNA vaccine demonstrated statistical superiority with an RVE of 34.5% over the control, driven primarily by robust responses to influenza A strains (H3N2 and H1N1). While antibody noninferiority was not met for B strains, the modRNA platform elicited superior T-cell responses across all strains. Safety profiles were comparable regarding serious adverse events, though the modRNA group exhibited significantly higher local and systemic reactogenicity (e.g., fever and fatigue) compared to the inactivated control.
Clinical Trial Summary: Phase 3 Evaluation of modRNA Influenza Vaccine
[Study Design and Participants]
Scale: Randomized, blinded trial involving 18,476 healthy or stable adults (18–64 years) across 242 sites in the US, South Africa, and the Philippines.
Cohorts: Participants were split 1:1 to receive either a 30 μg modRNA vaccine (n=9,225) or a standard inactivated control (FLUZONE) (n=9,251).
Demographics: Mean age 43; 73.6% White; 25.1% presented with at least one risk factor for severe influenza.
[Primary Efficacy Results]
Relative Vaccine Efficacy (RVE): The modRNA vaccine achieved an RVE of 34.5% (95% CI, 7.4 to 53.9) relative to the control, meeting criteria for both noninferiority and statistical superiority.
Strain Specificity: Efficacy was primarily observed against A/H3N2 and A/H1N1. Due to the 2022-2023 season being dominated by Type A viruses, insufficient data was collected to determine efficacy against B strains.
[Immunogenicity Profile]
Antibody Response (HAI): The modRNA vaccine met noninferiority margins for A/H3N2 and A/H1N1 strains. However, it failed to meet noninferiority for B/Yamagata and B/Victoria strains in Hemagglutination Inhibition (HAI) assays.
Cell-Mediated Immunity: The modRNA vaccine elicited significantly higher geometric mean factor increases in CD4+ and CD8+ T-cell expression of interferon-γ across all four strains compared to the control, maintained through 6 months.
[Safety and Reactogenicity]
Local and Systemic Events: Reactogenicity was higher in the modRNA group (70.1% local; 65.8% systemic) than the control (43.1% local; 48.7% systemic).
Common Symptoms: Pain at injection site, fatigue, and headache were the most reported. Fever (≤40.0°C) occurred in 5.6% of modRNA recipients vs. 1.7% of control recipients.
Serious Adverse Events (SAEs): SAEs through 6 months were low and balanced (~1.0% in both groups). No cases of myocarditis or pericarditis were confirmed.
[Key Takeaways and Clinical Implications]
Superiority in Type A: The modRNA platform provides improved protection against prevalent Influenza A strains over traditional egg-based/inactivated vaccines.
Platform Advantages: The findings support the modRNA platform’s potential for rapid manufacturing, precise strain matching, and avoidance of egg-adaptive mutations.
Reactogenicity Trade-off: While more effective, the modRNA vaccine carries a higher burden of transient, mild-to-moderate systemic side effects compared to traditional inactivated vaccines.
Ongoing Research: Further study is required to evaluate efficacy in pediatric, geriatric, and immunocompromised populations, as well as its performance against high-prevalence Influenza B seasons.